|Wednesday, October 20, 2010||Contact: Hallie Lewis (859) 224-2848|
|RMTC Makes Therapeutic Withdrawal Time Recommendations,|
Announces Progress of Its DTI Task Force
Based on the recommendation of its Scientific Advisory Committee, the Racing Medication and Testing Consortium (RMTC) board of directors has recommended scientifically identified withdrawal guidelines and plasma thresholds for the short-acting bronchodilator glycopyrrolate, the muscle relaxant methocarbamol and four anabolic steroids, three of which are endogenous (naturally occurring) in the horse. A recommendation for the non-steroidal anti-inflammatory medication firocoxib has also been approved pending resolution of one outstanding issue.
“Administration studies on these medications were developed and funded by the RMTC over the past few years in an effort to provide horsemen and practicing veterinarians with withdrawal guidelines that will enable the therapeutic use of these medications without compromising the integrity of racing competition or the welfare of our human and equine athletes,” said Dr. Rick Arthur, chair of the RMTC Scientific Advisory Committee and equine medical director for the California Horse Racing Board.
“The results of these studies have been eagerly anticipated by the industry, and we will continue to conduct important research on other therapeutic medications that are commonly used in managing the health of racehorses.”
The board made these recommendations at its meeting at the University of California-Davis on October 12, 2010.
The specific recommendations are as follows:
In addition, the RMTC board of directors approved a plasma threshold of 10 micrograms/ml for DMSO, which would allow for the use of DMSO as a topical leg paint but would not allow for the oral or intravenous administration of the drug. The board also recommended that DMSO be reclassified by the RCI Drug Testing Standards and Practices Committee to a Class 4 substance when appearing in samples in excess of the threshold concentration.
Based on a report provided by the Scientific Advisory Committee, the RMTC board expects to be able to issue recommendations for acepromazine, pyrilamine, mepivacaine, lidocaine, procaine and butorphanol at its next full meeting in March 2011.
Also at the meeting, RMTC Executive Director Dr. Scot Waterman provided an update on the progress of the RMTC Drug Testing Initiatives Task Force, which has been working toward drug testing quality assurance and laboratory accreditation since its inception in 2008. He noted that before the task force was initiated, only five of the 18 laboratories conducting drug testing on racehorses were accredited to ISO 17025 standards. Dr. Waterman predicted that that number will increase to 11 out of 19 laboratories by the end of 2011. In addition, three additional laboratories have expressed an interest in becoming RMTC-accredited following RMTC Vice Chairman Alan Foreman’s remarks at The Jockey Club Round Table Conference in August.
“We are thrilled with the commissions’ and their laboratories’ response to the challenge laid out by Mr. Foreman as part of his remarks at The Jockey Club Round Table Conference,” said Dr. Waterman. “The successful implementation of this program will improve industry confidence in its laboratory infrastructure and put our labs on par with any in the world.”
In other RMTC business:
“I would like to thank Dr. Scott Stanley and everyone at the Ken Maddy laboratory who helped host our group at this incredible facility,” said RMTC Chairman Dr. Robert Lewis. “We truly appreciated their hospitality and willingness to provide our board members with a unique learning experience.”
The RMTC consists of 25 racing industry stakeholders and organizations that represent Thoroughbred, Standardbred, American Quarter Horse and Arabian racing. The organization works to develop and promote uniform rules, policies and testing standards at the national level; coordinate research and educational programs that seek to ensure the integrity of racing and the health and welfare of racehorses and participants; and protect the interests of the racing public.
For additional information, visit the RMTC website at rmtcnet.com or contact Hallie Lewis, RMTC director of communications, at (859) 224-2848.